Literature DB >> 22328451

Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years.

Benedetta Bodini1, Mara Cercignani, Zhaleh Khaleeli, David H Miller, Maria Ron, Sophie Penny, Alan J Thompson, Olga Ciccarelli.   

Abstract

We aim to identify specific areas of white matter (WM) and grey matter (GM), which predict disability progression and cognitive dysfunction after five years in patients with primary-progressive multiple sclerosis (PPMS). Thirty-two patients with early PPMS were assessed at baseline and after five years on the Expanded Disability Status Scale (EDSS), and EDSS step-changes were calculated. At year five, a subgroup of 25 patients and 31 healthy controls underwent a neuropsychological assessment. Baseline imaging consisted of dual-echo (proton density and T2-weighted), T1-weighted volumetric, and diffusion tensor imaging. Fractional anisotropy (FA) maps were created, and fed into tract-based spatial statistics. To compensate for the potential bias introduced by WM lesions, the T1 volumes underwent a lesion-filling procedure before entering a voxel-based morphometry protocol. To investigate whether FA and GM volume predicted EDSS step-changes over five years and neuropsychological tests scores at five years, voxelwise linear regression analyses were performed. Lower FA in the splenium of the corpus callosum (CC) predicted a greater progression of disability over the follow-up. Lower FA along the entire CC predicted worse verbal memory, attention and speed of information processing, and executive function at five years. GM baseline volume did not predict any clinical variable. Our findings highlight the importance of damage to the interhemispheric callosal pathways in determining physical and cognitive disability in PPMS. Disruption of these pathways, which interconnect motor and cognitive networks between the two hemispheres, may result in a disconnection syndrome that contributes to long-term physical and cognitive disability.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22328451      PMCID: PMC6870474          DOI: 10.1002/hbm.21499

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  48 in total

Review 1.  Intentional maps in posterior parietal cortex.

Authors:  Richard A Andersen; Christopher A Buneo
Journal:  Annu Rev Neurosci       Date:  2002-03-27       Impact factor: 12.449

2.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

3.  Multiple sclerosis as an "inside-out" disease.

Authors:  Jeroen J G Geurts; Evert-Jan Kooi; Maarten E Witte; Paul van der Valk
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

4.  Nonrigid registration of multiple sclerosis brain images using lesion inpainting for morphometry or lesion mapping.

Authors:  Michaël Sdika; Daniel Pelletier
Journal:  Hum Brain Mapp       Date:  2009-04       Impact factor: 5.038

5.  Cerebral commissurotomy. A second case report.

Authors:  J E Bogen; E D Fisher; P J Vogel
Journal:  JAMA       Date:  1965-12-20       Impact factor: 56.272

6.  Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis.

Authors:  R A Dineen; J Vilisaar; J Hlinka; C M Bradshaw; P S Morgan; C S Constantinescu; D P Auer
Journal:  Brain       Date:  2008-10-25       Impact factor: 13.501

7.  Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging.

Authors:  Bernard D Coombs; Alan Best; Mark S Brown; David E Miller; John Corboy; Monika Baier; Jack H Simon
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

Review 9.  The neural basis of episodic memory: evidence from functional neuroimaging.

Authors:  Michael D Rugg; Leun J Otten; Richard N A Henson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-08-29       Impact factor: 6.237

Review 10.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

Authors:  David H Miller; Frederik Barkhof; Joseph A Frank; Geoffrey J M Parker; Alan J Thompson
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

View more
  15 in total

Review 1.  Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.

Authors:  Christian Enzinger; Frederik Barkhof; Olga Ciccarelli; Massimo Filippi; Ludwig Kappos; Maria A Rocca; Stefan Ropele; Àlex Rovira; Torben Schneider; Nicola de Stefano; Hugo Vrenken; Claudia Wheeler-Kingshott; Jens Wuerfel; Franz Fazekas
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

2.  Widespread White Matter Differences in Children and Adolescents with Autism Spectrum Disorder.

Authors:  V M Vogan; B R Morgan; R C Leung; E Anagnostou; K Doyle-Thomas; M J Taylor
Journal:  J Autism Dev Disord       Date:  2016-06

3.  Mapping lesion, structural disconnection, and functional disconnection to symptoms in semantic aphasia.

Authors:  Nicholas E Souter; Xiuyi Wang; Hannah Thompson; Katya Krieger-Redwood; Ajay D Halai; Matthew A Lambon Ralph; Michel Thiebaut de Schotten; Elizabeth Jefferies
Journal:  Brain Struct Funct       Date:  2022-07-04       Impact factor: 3.270

4.  Associations between corpus callosum damage, clinical disability, and surface-based homologous inter-hemispheric connectivity in multiple sclerosis.

Authors:  Andrew W Russo; Kirsten E Stockel; Sean M Tobyne; Chanon Ngamsombat; Kristina Brewer; Aapo Nummenmaa; Susie Y Huang; Eric C Klawiter
Journal:  Brain Struct Funct       Date:  2022-05-10       Impact factor: 3.270

5.  A novel approach with "skeletonised MTR" measures tract-specific microstructural changes in early primary-progressive MS.

Authors:  Benedetta Bodini; Mara Cercignani; Ahmed Toosy; Nicola De Stefano; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Hum Brain Mapp       Date:  2013-04-24       Impact factor: 5.038

6.  Early white matter changes in childhood multiple sclerosis: a diffusion tensor imaging study.

Authors:  A Blaschek; D Keeser; S Müller; I K Koerte; A Sebastian Schröder; W Müller-Felber; F Heinen; B Ertl-Wagner
Journal:  AJNR Am J Neuroradiol       Date:  2013-05-16       Impact factor: 3.825

7.  Whole brain 3D MR fingerprinting in multiple sclerosis: a pilot study.

Authors:  Thomaz R Mostardeiro; Ananya Panda; Norbert G Campeau; Robert J Witte; Nicholas B Larson; Yi Sui; Aiming Lu; Kiaran P McGee
Journal:  BMC Med Imaging       Date:  2021-05-22       Impact factor: 1.930

8.  Serum insulin-like growth factor-I levels are associated with improved white matter recovery after traumatic brain injury.

Authors:  Claire Feeney; David J Sharp; Peter J Hellyer; Amy E Jolly; James H Cole; Gregory Scott; David Baxter; Sagar Jilka; Ewan Ross; Timothy E Ham; Peter O Jenkins; Lucia M Li; Nikos Gorgoraptis; Mark Midwinter; Anthony P Goldstone
Journal:  Ann Neurol       Date:  2017-07       Impact factor: 10.422

9.  Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.

Authors:  Christina Engl; Laura Tiemann; Sophia Grahl; Matthias Bussas; Paul Schmidt; Viola Pongratz; Achim Berthele; Annkathrin Beer; Christian Gaser; Jan S Kirschke; Claus Zimmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2020-04-23       Impact factor: 4.849

10.  Risk acceptance in multiple sclerosis patients on natalizumab treatment.

Authors:  Carmen Tur; Mar Tintoré; Ángela Vidal-Jordana; Denis Bichuetti; Pablo Nieto González; María Jesús Arévalo; Georgina Arrambide; Elisenda Anglada; Ingrid Galán; Joaquín Castilló; Carlos Nos; Jordi Río; María Isabel Martín; Manuel Comabella; Jaume Sastre-Garriga; Xavier Montalban
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.